PF-04457845

PF-04457845
Clinical data

ATC code	None
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name N-pyridazin-3-yl-4-[(3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl)methylidene]piperidine-1-carboxamide
PubChem CID	24771824
ChemSpider	26390839
UNII	H4C81M8YYW
ChEMBL	CHEMBL1651534
Chemical and physical data
Formula	C₂₃H₂₀F₃N₅O₂
Molar mass	455.432 g/mol
3D model (Jmol)	Interactive image
SMILES n4ncccc4NC(=O)N(CC3)CC\C3=C/c2cc(ccc2)Oc(cc1)ncc1C(F)(F)F
InChI InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32) Key:BATCTBJIJJEPHM-UHFFFAOYSA-N

PF-04457845 is a potent and exquisitely selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀ of 7.2nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.

It has been well tolerated in human trials even at high dose ranges with no evidence for cognitive dysfunction, and has completed Phase II clinical trials for the treatment of osteoarthritis, but was found to be ineffective.

...
Wikipedia